help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH

First Published Online November 19, 2008
The Oncologist, doi: 10.1634/theoncologist.2008-0130
© 2008 AlphaMed Press
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2008-0130v1
13/12/1285    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dietrich, J.
Right arrow Articles by Meyers, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dietrich, J.
Right arrow Articles by Meyers, C.

Neuro-Oncology

Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy

Jörg Dietricha, Michelle Monjeb, Jeffrey Wefelc, Christina Meyersc

aDepartment of Neurology, Division of Neuro-Oncology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; bDepartments of Neurology and Developmental Biology, Stanford Institutes of Medicine, Stanford University, Palo Alto, California, USA; cDepartment of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Key Words. Neurotoxicity • Cognitive dysfunction • Chemotherapy • Radiation therapy • Progenitor cells • Neural stem cells

Correspondence: Correspondence: Jörg Dietrich, M.D., Ph.D., Department of Neurology, Division of Neuro-Oncology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA. Telephone: 617-726-3650; Fax: 617-643-2591; e-mail: jdietrich1{at}partners.org

Received June 10, 2008; accepted for publication October 26, 2008.

ABSTRACT

Standard oncological therapies, such as chemotherapy and cranial radiotherapy, frequently result in a spectrum of neurocognitive deficits that includes impaired learning, memory, attention, and speed of information processing. In addition to classical mechanisms of neurotoxicity associated with chemo- and radiotherapy, such as radiation necrosis and leukoencephalopathy, damage to dynamic progenitor cell populations in the brain is emerging as an important etiologic factor. Radiation- and chemotherapy-induced damage to progenitor populations responsible for maintenance of white matter integrity and adult hippocampal neurogenesis is now believed to play a major role in the neurocognitive impairment many cancer survivors experience.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2008 by AlphaMed Press.